Among the most frequent urological cancers (UCs) are prostate, kidney, and bladder cancer (BCa) [1]. Age, tobacco utilization, contact with some compounds, and a family heritage of carcinoma are all associated with risk for UCs [2], [3]. UCs constitute around 10% of all cancers, with prostate cancer (PCa) affecting 29% of cancers in males [4]. Treatment options for UCs vary according to their nature and phase but can involve surgery, radiotherapy, chemotherapy (CT), and immunotherapy [5], [6], [7]. Although surgery is the single most viable option for UCs, the 5-year survival statistic remains inadequate [8], [9]. Androgen elimination is frequently the best therapeutic choice for locally advanced and aggressive PCa [10]. This therapy strategy significantly improves the average well-being of individuals [11]. Focused and immunological response medicines have been found to enhance the longevity of people with renal cell carcinoma (RCC), with tyrosine kinase antagonists being frequently utilized in clinical therapy [12], [13]. Individuals with BCa, on the other hand, have an elevated rate of recurrence and are more likely to develop distant tumors. The outlook of individuals with severe or aggressive BCa is dismal [14], [15]. Afterward, replenishment with BCG or gemcitabine bladder implantation enhances persons' living standards and successfully lowers the chance of recurrence [16], [17]. Despite major advancements in BCa therapy, early detection leads to the best potential outcomes for patients. As a result, identifying novel indicators for malignancy is an important and ongoing therapeutic goal, with lncRNAs as potential biomarkers for illness [18], [19], [20].

Long non-coding RNAs (lncRNAs) became known as crucial mediators in oncology. The most recent use of genetic sequencing to investigate an increasing quantity of tumor-related RNAs has revealed numerous lncRNAs whose abnormal activity has been associated with many forms of cancers [21]. Several of the clinically discovered genes have been linked to malignant alterations. These lncRNAs, in particular, perform critical functions in gene regulation and impact several elements of cellular homeostasis like as development, survival, motility, and genomic stability. Abnormal lncRNA expression has been linked to malignancies, meaning that certain lncRNAs either encourage or hinder carcinogenesis [22], [23]. lncRNAs have been related to numerous essential tumor features through collaboration with additional macromolecules in biology such as DNA, proteins, and RNA. The mechanisms by which lncRNAs impact various cancers have been studied, with an emphasis on epigenetic and genetic modifications in general. The identification of cancer-associated lncRNAs (CA-lncRNAs), in addition to links between CA-lncRNAs and gene targets, may contribute to the advancement of detection and treatment methods for battling cancers [24], [25], [26], [27].

MALAT1 (Metastasis-Associated Lung Adenocarcinoma Transcript 1) is a lncRNA that is upregulated in several tumors, most notably non-small cell lung cancer (NSCLC) and contributes to the emergence and advancement of these conditions. Its relevance stretches to functioning as an indicator for NSCLC individuals' early identification, harshness review, and outcome analysis [28]. MALAT1 influences biological processes via a variety of processes, involving gene expression oversight, differentiating the splicing of pre-mRNAs, protein metabolism supervision, epigenetic modification arbitration, advancement of nuclear and cytoplasmic transfer of proteins, and behaving as an endogenous miRNA sponge (EmiRNAs) [28], [29], [30]. MALAT1 has also been studied in esophageal and gastric cancer (GC), whereby its improper functioning has predictive and treatment effects [31]. MALAT1 also functions as a competitive endogenous RNA (ceRNA), attaching to microRNAs (miRNAs) and recovering downstream mRNA translation and functioning. Cell development, apoptosis, movement, invasion, and cell cycle halting are all influenced by this regulatory system [29]. MALAT1 is implicated in the control of stem cell lineage commitment and maturation via several pathways in the setting of bone remodeling [32], [33]. As a whole, MALAT1 is a versatile cancer regulator that is involved in a diverse set of physiological processes and illnesses, making it a topic of substantial investigation.

The major purpose of this study is to provide a detailed analysis of the numerous functions of the lncRNA MALAT1 in UCs. This in-depth article aims to thoroughly assess and connect the current research, providing an in-depth comprehension of MALAT1's distinguished engagement in the initiation, development, and clinical results of UCs that extend to PCa, BCa, and RCC. By achieving these goals, the review hopes to provide helpful knowledge into the precise activities of MALAT1 in UCs, providing the framework for future research. Furthermore, the results might help to develop tailored screening and treatment techniques for these cancers, filling major holes in existing investigations and therapeutic techniques.